PH26262A - Tertiary hydroxyalkyl-anthines their use and pharmaceutical compositions containing them - Google Patents

Tertiary hydroxyalkyl-anthines their use and pharmaceutical compositions containing them Download PDF

Info

Publication number
PH26262A
PH26262A PH34027A PH34027A PH26262A PH 26262 A PH26262 A PH 26262A PH 34027 A PH34027 A PH 34027A PH 34027 A PH34027 A PH 34027A PH 26262 A PH26262 A PH 26262A
Authority
PH
Philippines
Prior art keywords
methyl
hydroxy
formula
mol
group
Prior art date
Application number
PH34027A
Other languages
English (en)
Inventor
Ulrich Gebert
Ismahan Okyayuzbaklouti
Werner Thorwart
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of PH26262A publication Critical patent/PH26262A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
PH34027A 1985-07-19 1986-07-17 Tertiary hydroxyalkyl-anthines their use and pharmaceutical compositions containing them PH26262A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19853525801 DE3525801A1 (de) 1985-07-19 1985-07-19 Tertiaere hydroxyalkylxanthine, verfahren zu ihrer herstellung, die sie enthaltenden arzneimittel und ihre verwendung

Publications (1)

Publication Number Publication Date
PH26262A true PH26262A (en) 1992-04-01

Family

ID=6276182

Family Applications (1)

Application Number Title Priority Date Filing Date
PH34027A PH26262A (en) 1985-07-19 1986-07-17 Tertiary hydroxyalkyl-anthines their use and pharmaceutical compositions containing them

Country Status (33)

Country Link
US (1) US4833146A (cs)
EP (1) EP0268585B1 (cs)
JP (1) JPH0788382B2 (cs)
KR (1) KR950001019B1 (cs)
CN (1) CN1026112C (cs)
AR (1) AR244689A1 (cs)
AT (1) ATE53211T1 (cs)
AU (1) AU588350B2 (cs)
BG (1) BG60767B2 (cs)
CA (1) CA1262248A (cs)
CS (1) CS272766B2 (cs)
DD (1) DD261156A5 (cs)
DE (2) DE3525801A1 (cs)
DK (1) DK157867C (cs)
ES (1) ES2001019A6 (cs)
FI (1) FI89921C (cs)
GR (1) GR861866B (cs)
HU (1) HU198486B (cs)
IE (1) IE59025B1 (cs)
IL (1) IL79457A0 (cs)
LT (1) LT3869B (cs)
LV (1) LV5703A3 (cs)
MA (1) MA20739A1 (cs)
MX (1) MX9254A (cs)
NO (1) NO165803C (cs)
NZ (1) NZ216888A (cs)
OA (1) OA08707A (cs)
PH (1) PH26262A (cs)
PT (1) PT83013B (cs)
RU (1) RU2051918C1 (cs)
TN (1) TNSN86111A1 (cs)
WO (1) WO1987000523A2 (cs)
ZA (1) ZA865374B (cs)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8621870D0 (en) * 1986-09-11 1986-10-15 Beecham Group Plc Active compounds
US5338741A (en) * 1986-10-27 1994-08-16 Nestec S.A. 1-hydroxyalkylxanthines and medicaments containing them
JP2661666B2 (ja) * 1988-02-19 1997-10-08 ヘキスト薬品工業株式会社 抗消化性潰瘍剤
GB8826595D0 (en) * 1988-11-14 1988-12-21 Beecham Wuelfing Gmbh & Co Kg Active compounds
DD298051A5 (de) * 1989-08-16 1992-02-06 ��@���������@�������k�� Verfahren zur herstellung eines therapeutischen agens zur behandlung von verdauungskrankheiten
GB8924392D0 (en) * 1989-10-30 1989-12-20 Bayer Ag Substituted cycloalkano/b/dihydroindole-and-indolesulphonamides
EP0430300A3 (en) * 1989-12-01 1992-03-25 Takeda Chemical Industries, Ltd. Xanthine derivatives, their production and use
DE3942872A1 (de) * 1989-12-23 1991-06-27 Hoechst Ag Verfahren zur enantioselektiven darstellung von ((omega)-1)-hydroxyalkylxanthinen
IT1240843B (it) * 1990-05-24 1993-12-17 Malesci Istituto Farmacobiologico Derivati xantinici 1-7 sostituiti ad attivita' antiasmatica, loro sali fisiologicamente accettabili, loro composizioni farmaceutiche e procedimento per la loro preparazione.
DE4019892A1 (de) * 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
US5039666A (en) * 1990-10-30 1991-08-13 Hoechst-Roussel Pharmaceuticals Inc. Aminoglycoside composition having substantially reduced nephrotoxicity induced by the aminoglycoside
DE69119700T2 (de) * 1990-11-07 1996-11-07 Hoechst Roussel Pharma Verwendung von Xanthinen zur Herstellung von Arzneimitteln zur Hemmung der Vermehrung menschlicher Retroviren
US6420374B1 (en) 1990-11-30 2002-07-16 Fred Hutchinson Cancer Research Center Use of xanthines as immunosuppressants and to inhibit allograft reactions
MX9203323A (es) * 1991-07-11 1994-07-29 Hoechst Ag El empleo de derivados de xantina para el tratamiento de lesiones secundarias de las celulas nerviosas y trastornos funcionales despues de traumas craneo-cerebrales.
TW209834B (cs) * 1991-12-11 1993-07-21 Hoechst Ag
ATE146078T1 (de) * 1992-02-22 1996-12-15 Hoechst Ag Verwendung von xanthinderivaten zur behandlung von muskelschädigungen nach vollständiger unterbrechung der blutzirkulation
PT584347E (pt) * 1992-03-04 2003-06-30 Cell Therapeutics Inc Compostos de xantina hidroxilados enantiomericos
EP0570831A2 (de) * 1992-05-20 1993-11-24 Hoechst Aktiengesellschaft Verwendung von Xanthinderivaten zur Behandlung von Nervenschädigungen nach Unterbrechung der Blutzirkulation
US5288721A (en) * 1992-09-22 1994-02-22 Cell Therapeutics, Inc. Substituted epoxyalkyl xanthines
US5817662A (en) * 1992-11-09 1998-10-06 Cell Therapeutics, Inc. Substituted amino alkyl compounds
US5473070A (en) * 1992-11-16 1995-12-05 Cell Therapeutics, Inc. Substituted long chain alcohol xanthine compounds
US6693105B1 (en) 1992-11-16 2004-02-17 Cell Therapeutics, Inc. Hydroxyl-containing compounds
US5780476A (en) * 1992-11-16 1998-07-14 Cell Therapeutics, Inc. Hydroxyl-containing xanthine compounds
US5866576A (en) * 1992-12-16 1999-02-02 Cell Therapeutics, Inc. Epoxide-containing compounds
AU6087894A (en) * 1993-01-14 1994-08-15 Cell Therapeutics, Inc. Acetal or ketal substituted therapeutic compounds
AU6092794A (en) * 1993-01-19 1994-08-15 Cell Therapeutics, Inc. Oxime-substituted therapeutic compounds
US5641783A (en) * 1993-11-12 1997-06-24 Cell Therapeutics, Inc. Substituted amino alcohol compounds
US5837703A (en) * 1993-03-31 1998-11-17 Cell Therapeutics, Inc. Amino-alcohol substituted cyclic compounds
US6020337A (en) * 1993-04-05 2000-02-01 Cell Therapeutics, Inc. Electronegative-substituted long chain xanthine compounds
AU1831395A (en) * 1994-01-14 1995-08-01 Cell Therapeutics, Inc. Method for treating diseases mediated by cellular proliferation in response to pdgf, egf, fgf and vegf
CA2183562A1 (en) * 1994-02-18 1995-08-24 J. Peter Klein Intracellular signalling mediators
US6103730A (en) * 1994-03-24 2000-08-15 Cell Therapeutics, Inc. Amine substituted compounds
US5801182A (en) * 1994-03-24 1998-09-01 Cell Therapeutics, Inc. Amine substituted compounds
US5807861A (en) * 1994-03-24 1998-09-15 Cell Therapeutics, Inc. Amine substituted xanthinyl compounds
DE19540798A1 (de) * 1995-11-02 1997-05-07 Hoechst Ag Alkylxanthinphosphonate und Alkylxanthinphosphinoxide und deren Verwendung als Arzneimittel
US5965555A (en) * 1996-06-07 1999-10-12 Hoechst Aktiengesellschaft Xanthine compounds having terminally animated alkynol side chains
ES2185837T3 (es) * 1996-06-07 2003-05-01 Hoechst Ag Utilizacion de derivados de teofilina para el tratamiento y la profilaxis de las enfermedades de choque, nuevos compuestos de xantina y procedimientos para su produccion.
US5981536A (en) * 1996-07-31 1999-11-09 Hoechst Aktiengesellschaft Use of xanthine derivatives for the modulation of apoptosis
US5856330A (en) * 1996-07-31 1999-01-05 Hoechst Aktiengesellschaft Use of xanthine derivatives for the inhibition of dephosphorylation of cofilin
DE19707655A1 (de) * 1997-02-26 1998-08-27 Hoechst Ag Kombinationspräparat zur Anwendung bei Demenz
US5985592A (en) * 1997-06-05 1999-11-16 Dalhousie University Uses for pentoxifylline or functional derivatives/metabolites thereof
US6294350B1 (en) 1997-06-05 2001-09-25 Dalhousie University Methods for treating fibroproliferative diseases
US6075029A (en) * 1998-01-02 2000-06-13 Cell Therapeutics, Inc. Xanthine modulators of metabolism of cellular P-450
US20030207901A1 (en) * 1999-07-27 2003-11-06 Cell Therapeutics, Inc. Hydroxyl-containing compounds
RU2157209C1 (ru) * 2000-03-23 2000-10-10 Открытое акционерное общество "Химико-фармацевтический комбинат "Акрихин" Улучшающее мозговое кровообращение, антиагрегатное средство и способ его получения
DE10042152A1 (de) * 2000-08-26 2002-03-28 Basf Coatings Ag Mit aktinischer Strahlung aktivierbares Thixotropierungsmittel, Verfahren zu seiner Herstellung und seine Verwendung
DE10122390A1 (de) * 2001-05-09 2002-11-28 Basf Coatings Ag Carbamat-und/oder Allophanatgruppen enthaltende, thermisch härtbare, thixotrope Gemische
DE10139262C1 (de) * 2001-08-09 2003-01-02 Basf Coatings Ag Rheologiehilfsmittel, Verfahren zu seiner Herstellung und seine Verwendung
EP1497387A1 (de) * 2002-04-24 2005-01-19 BASF Coatings Aktiengesellschaft Carbamat- und/oder allophanatgruppen enthaltende, thermisch härtbare, thixotrope gemische
KR100872788B1 (ko) * 2002-05-28 2008-12-09 엘지전자 주식회사 드럼세탁기
US8686090B2 (en) * 2003-12-10 2014-04-01 Basf Coatings Gmbh Use of urea crystals for non-polymeric coatings
US20080081816A1 (en) * 2006-10-03 2008-04-03 Kaohsiung Medical University Anti-inflammation activity of newly synthesized xanthine derivatives kmup-1 and kmup-3
EP2265334A2 (en) 2008-02-29 2010-12-29 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
KR20110014974A (ko) * 2008-03-31 2011-02-14 썬 파마슈티컬 인더스트리스 리미티드 모르피난 유사체의 개선된 제조 방법
US8263601B2 (en) 2009-02-27 2012-09-11 Concert Pharmaceuticals, Inc. Deuterium substituted xanthine derivatives
CA2771331A1 (en) 2009-09-02 2011-03-10 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
WO2011028820A1 (en) 2009-09-02 2011-03-10 Concert Pharmaceuticals, Inc. Substituted derivatives of bicyclic [4.3.0] heteroaryl compounds
WO2012031073A1 (en) 2010-09-01 2012-03-08 Concert Pharmaceuticals, Inc. Process for preparing an enantiomerically enriched, deuterated secondary alcohol from a corresponding ketone without reducing deuterium incorporation
US9085788B2 (en) 2010-09-01 2015-07-21 Concert Pharmaceuticals, Inc. Process for preparing an enantiomerically enriched, deuterated secondary alcohol from a corresponding ketone without reducing deuterium incorporation
WO2013155465A1 (en) 2012-04-13 2013-10-17 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1245969B (de) * 1967-08-03 VEB Arzneimittelwerk Dresden, Radebeul Verfahren zur Herstellung von Xanthinderivaten
US2517410A (en) * 1947-08-15 1950-08-01 Searle & Co Hydroxy alkyl xanthines and the production thereof
FR1211333A (fr) * 1955-10-19 1960-03-15 Boehringer Sohn Ingelheim Perfectionnements apportés aux procédés pour fabriquer des oxyalcoylxanthines
DE2335170C2 (de) * 1973-07-11 1989-07-20 Hoechst Ag, 6230 Frankfurt 1,3-Dialkyl-7-(hydroxyalkyl)-xanthine, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
US4576947A (en) * 1967-12-16 1986-03-18 Hoechst Aktiengesellschaft Pharmaceutical compositions
BE795345A (fr) * 1972-02-19 1973-08-13 Albert Ag Chem Werke MEDICAMENT UTILE NOTAMMENT POUR L'IRRIGATION CEREBRALE, PROCEDE DE PREPARATION DE SES MATIERES ACTIVES ET CES MATIERES ElLES-MEMES
CH622519A5 (en) * 1974-07-05 1981-04-15 Hoechst Ag Process for the preparation of hydroxyalkylxanthines
DE2432702C2 (de) * 1974-07-08 1983-01-20 Hoechst Ag, 6000 Frankfurt Verfahren zur Herstellung von Hydroxyalkylxanthinen
CA1075690A (en) * 1974-12-13 1980-04-15 Hoechst Aktiengesellschaft Xanthine derivatives
EP0017478B1 (en) * 1979-04-05 1983-03-30 BEECHAM - WUELFING GmbH & Co. KG Dialkoxy- and dioxacycloalkyl-alkyltheobromines, pharmaceutical compositions containing them and their preparation
JPS5838284A (ja) * 1981-09-01 1983-03-05 Teikoku Chem Ind Corp Ltd １−（５′−オキソヘキシル）−３，７−ジメチルキサンチンの製造方法
DE3138397A1 (de) * 1981-09-26 1983-04-07 Hoechst Ag, 6230 Frankfurt "arzneimittel, darin enthaltene vicinale dihydroxyalkylxanthine und herstellungsverfahren fuer diese xanthinverbindungen"
US4575795A (en) * 1983-04-01 1986-03-11 Honeywell Information Systems Inc. Apparatus for detecting a predetermined character of a data string

Also Published As

Publication number Publication date
OA08707A (en) 1989-03-31
CA1262248A (en) 1989-10-10
FI880174A0 (fi) 1988-01-15
DK139287A (da) 1987-03-18
FI880174L (fi) 1988-01-15
JPH0788382B2 (ja) 1995-09-27
IE59025B1 (en) 1993-12-15
CN86105835A (zh) 1987-01-14
ATE53211T1 (de) 1990-06-15
NO165803B (no) 1991-01-02
WO1987000523A3 (fr) 1987-02-26
CS545386A2 (en) 1990-04-11
AU6143986A (en) 1987-02-10
LV5703A3 (lv) 1995-02-20
DE3525801A1 (de) 1987-01-22
CS272766B2 (en) 1991-02-12
GR861866B (en) 1986-11-17
HU198486B (en) 1989-10-30
IL79457A0 (en) 1986-10-31
FI89921C (fi) 1993-12-10
IE861917L (en) 1987-01-19
DD261156A5 (de) 1988-10-19
KR870700623A (ko) 1987-12-30
EP0268585B1 (de) 1990-05-30
NO871111D0 (no) 1987-03-18
KR950001019B1 (ko) 1995-02-07
NZ216888A (en) 1989-05-29
ZA865374B (en) 1987-02-25
EP0268585A1 (de) 1988-06-01
TNSN86111A1 (fr) 1990-01-01
WO1987000523A2 (en) 1987-01-29
AU588350B2 (en) 1989-09-14
PT83013B (pt) 1989-01-30
DE3671627D1 (de) 1990-07-05
US4833146A (en) 1989-05-23
MA20739A1 (fr) 1987-04-01
HUT47274A (en) 1989-02-28
AR244689A1 (es) 1993-11-30
JPS63501149A (ja) 1988-04-28
MX9254A (es) 1993-06-01
BG60767B2 (bg) 1996-02-29
CN1026112C (zh) 1994-10-05
RU2051918C1 (ru) 1996-01-10
DK157867C (da) 1990-07-30
PT83013A (de) 1986-08-01
NO871111L (no) 1987-03-18
DK157867B (da) 1990-02-26
LTIP1467A (en) 1995-05-25
NO165803C (no) 1991-04-10
FI89921B (fi) 1993-08-31
ES2001019A6 (es) 1988-04-16
DK139287D0 (da) 1987-03-18
LT3869B (en) 1996-04-25

Similar Documents

Publication Publication Date Title
PH26262A (en) Tertiary hydroxyalkyl-anthines their use and pharmaceutical compositions containing them
US12049461B2 (en) 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
US10519188B2 (en) Cyclic di-nucleotide compounds and methods of use
EP0920438B1 (en) N6 heterocyclic substituted adenosine derivatives
EP3437644B1 (en) Compounds for use in the treatment of pulmonary hypertension
JPH06510299A (ja) １−置換　１Ｈ−イミダゾ（４，５−ｃ）キノリン−４−アミン，中間体及び医薬用組成物
AU739417B2 (en) Therapeutic agent for erection dysfunction
US4663326A (en) Pyrazolo[4,3-d]pyrimidine-5,7-(4H,6H)dione or -5-thione-7-one analogs
CS262690B2 (en) Process for preparing 1-/hydroxystyryl/-5h-2,3-benzodiazepines
JP3436547B2 (ja) 頭蓋脳外傷後の二次的神経細胞損傷および機能疾患を治療するためのキサンチン誘導体の使用
JPH0649702B2 (ja) ベンゼン縮合複素環化合物
KR100373948B1 (ko) 호산성과립구의병적인과반응성을감소시키기위한크산틴유도체를포함하는약제학적조성물,신규한크산틴화합물및이의제조방법
JPH02501302A (ja) ベンゾジアジノン‐ピリドン化合物並びに該化合物を含有する強心性組成物、及びその使用方法
JP2977242B2 (ja) 抗消化性潰瘍剤
JPH10212235A (ja) 抗腫瘍剤
SK68599A3 (en) Guanidinylamino heterocycle compounds useful as alpha-2 adrenoceptor agonists
JPH08507532A (ja) 抗腫瘍組成物及び処置方法
WO2007000771A2 (en) Fused quinazolinone derivatives and uses thereof
JP3571114B2 (ja) 麻薬拮抗剤
JP2002543046A (ja) ピリミド［６，１−ａ］イソキノリン−４−オン誘導体
CS272798B2 (en) Method of tertiaryhydroxyalkylanthine production
HK40000144B (en) Compounds for use in the treatment of pulmonary hypertension
HK40000144A (en) Medicine
AU2013204105A1 (en) Compounds for modulating TRPV3 function